GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Precision BioSciences Inc (NAS:DTIL) » Definitions » Enterprise Value

Precision BioSciences (Precision BioSciences) Enterprise Value : $-17.49 Mil (As of Apr. 26, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Precision BioSciences Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Precision BioSciences's Enterprise Value is $-17.49 Mil. Precision BioSciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-60.27 Mil. Therefore, Precision BioSciences's EV-to-EBIT ratio for today is 0.29.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Precision BioSciences's Enterprise Value is $-17.49 Mil. Precision BioSciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-52.01 Mil. Therefore, Precision BioSciences's EV-to-EBITDA ratio for today is 0.34.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Precision BioSciences's Enterprise Value is $-17.49 Mil. Precision BioSciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $48.73 Mil. Therefore, Precision BioSciences's EV-to-Revenue ratio for today is -0.36.


Precision BioSciences Enterprise Value Historical Data

The historical data trend for Precision BioSciences's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Precision BioSciences Enterprise Value Chart

Precision BioSciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial 529.66 360.18 316.13 -32.57 -39.81

Precision BioSciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -32.57 -46.88 -49.28 -58.89 -39.81

Competitive Comparison of Precision BioSciences's Enterprise Value

For the Biotechnology subindustry, Precision BioSciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Precision BioSciences's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Precision BioSciences's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Precision BioSciences's Enterprise Value falls into.



Precision BioSciences Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Precision BioSciences's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Precision BioSciences's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Precision BioSciences  (NAS:DTIL) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Precision BioSciences's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-17.493/-60.265
=0.29

Precision BioSciences's current Enterprise Value is $-17.49 Mil.
Precision BioSciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-60.27 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Precision BioSciences's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=-17.493/-52.01
=0.34

Precision BioSciences's current Enterprise Value is $-17.49 Mil.
Precision BioSciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-52.01 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Precision BioSciences's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=-17.493/48.727
=-0.36

Precision BioSciences's current Enterprise Value is $-17.49 Mil.
Precision BioSciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $48.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Precision BioSciences Enterprise Value Related Terms

Thank you for viewing the detailed overview of Precision BioSciences's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Precision BioSciences (Precision BioSciences) Business Description

Traded in Other Exchanges
Address
302 East Pettigrew Street, Dibrell Building, Suite A-100, Durham, NC, USA, 27701
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Executives
J. Jefferson Smith 10 percent owner C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Alan List officer: Chief Medical Officer C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701
Michael Amoroso director, officer: President and CEO 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Dario Scimeca officer: General Counsel C/O PRECISION BIOSCIENCES, INC., 302 E. PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
John Alexander Kelly officer: Interim CFO C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Pharma Ag Novartis 10 percent owner LICHTSTRASSE 35, CH-4002, BASEL V8
Ag Novartis 10 percent owner LICHTSTRASSE 35, BASEL V8 CH 4056
Derek Jantz director, 10 percent owner, officer: Chief Scientific Officer C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Melinda Brown director 10 HUDSON YARDS, NEW YORK NY 10001
Shari Lisa Pire director C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701
Samuel C. Wadsworth director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
David S. Thomson officer: Chief Development Officer C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Stanley Frankel director C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701
Matthew R. Kane director, 10 percent owner, officer: President and CEO C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Shane Barton officer: VP & Corporate Controller C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701

Precision BioSciences (Precision BioSciences) Headlines

From GuruFocus